Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.
Read original at benzingaStocks · News reference
Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 2:00 PM
- Checked
- Aug 3, 2026, 2:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.
Read original at globenewswire-incTD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.
Read original at benzinga